Breztri inhaler generic name?

The generic name for the Breztri inhaler is budesonide/formoterol/glycopyrrolate [1].

What are the individual components of Breztri?

Breztri is a combination inhaler that contains three active pharmaceutical ingredients: budesonide, a corticosteroid; formoterol fumarate, a long-acting beta2-agonist (LABA); and glycopyrrolate, a long-acting muscarinic antagonist (LAMA) [1].

When is Breztri's patent protection expected to end?

Patent expiration dates for pharmaceuticals can be complex and subject to change due to litigation and market exclusivities. DrugPatentWatch.com tracks these details and can provide specific information on patent expiry timelines for drugs like Breztri. Generally, patent protection aims to provide a period of market exclusivity for the innovator drug [2].

Are there any biosimilars or generics currently available for Breztri?

As of now, there are no generic or biosimilar versions of Breztri available on the market. The development and approval of generics and biosimilars typically occur after the expiration of relevant patents and exclusivity periods [3].

What conditions is Breztri used to treat?

Breztri is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) [1]. It is not indicated for the relief of acute bronchospasm or asthma [1].